Last reviewed · How we verify

NCT03801122: TTRAP-Bleeding

Evolution of Thromboelastography During Tranexamic Acid Treatment

Completed Phase 2 Last updated 6 May 2023
What this trial tests

Phase 2 trial testing Tranexamic acid in Hematological Malignancies Treated With Intensive Chemotherapy in 18 participants. Completed in 11 July 2022.

Timeline
5 March 2019
Primary endpoint
9 March 2022
11 July 2022

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Saint Etienne
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment18
Start date5 March 2019
Primary completion9 March 2022
Estimated completion11 July 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Who can join

18 and older, any sex, with Hematological Malignancies Treated With Intensive Chemotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with hematological malignancies are at increased risk of bleeding, especially during intensive chemotherapy. The aim of this study is to compare by thromboelastography changes during the intensive chemotherapy in patients with hematological malignancies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Challenges and Advances in Managing Thrombocytopenic Cancer Patients.
    Leader A, Hofstetter L, Spectre G. · · 2021 · cited 23× · PMID 33799591 · DOI 10.3390/jcm10061169

Verify or expand the search:

Other trials of Tranexamic acid

Trials testing the same drug.

Other Centre Hospitalier Universitaire de Saint Etienne trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03801122.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing